フェニルケトン尿症（PKU）の世界市場レポート 2025年

フェニルケトン尿症（PKU）市場規模は、今後数年間で力強い成長が見込まれます。2029年には13億米ドルにまで成長し、CAGRは8.8％となります。予測期間の成長は、遺伝子治療の採用増加、酵素補充療法の拡大、希少疾患調査への投資増加、個別化医療への需要の高まり、PKU治療適用に対する政府支援などに起因すると考えられます。主な動向としては、RNAベースの治療法の開発、PKU管理のためのデジタルヘルスソリューションの台頭、バイオテクノロジー企業と研究機関の共同研究の増加、非食餌療法代替療法への注目、PKU患者のための遠隔医療サービスの拡大などが挙げられます。

遺伝性疾患の罹患率の上昇が、今後数年間のフェニルケトン尿症（PKU）市場の成長を牽引すると予想されます。遺伝性疾患は、遺伝子や染色体の変異、欠失、重複など、個人のDNAの異常によって引き起こされる病状です。これらの疾患の有病率の増加は、母体年齢の上昇、環境の影響、診断技術の進歩、認知度の向上などの要因によるもので、発見率の向上につながります。フェニルケトン尿症は、遺伝性の酵素欠損がいかに重篤な代謝合併症を引き起こすかを示すことにより、遺伝性疾患を理解する上で重要な役割を果たしています。例えば、2024年3月、英国を拠点とする登録慈善団体ジーン・ピープルは、遺伝的疾患が子供の約25人に1人に影響を及ぼし、英国の240万人以上の子供と成人に影響を与えていると報告しました。さらに、英国では毎年約3万人の新生児と子供が遺伝病と診断されています。その結果、遺伝性疾患の発生率の増加がフェニルケトン尿症（PKU）市場の拡大に拍車をかけています。

フェニルケトン尿症（PKU）市場の主要企業は、PKU治療の有効性と安全性を高めるための技術的進歩に注力しています。そのような技術革新の一つがフィジオミミック技術の利用であり、これは薬物の吸収と代謝を改善するために人間の生理的状態を再現するものです。フィジオミミック技術は、複雑なヒトの生物学をシミュレートし、ヒトの薬物反応を正確に予測するために設計されたハードウェア、消耗品、アッセイプロトコルのセットで構成されています。例えば、2022年10月、スイスを拠点とするバイオ医薬品会社Relief Therapeutics Holding SAは、PKU Golikeの発売を発表しました。この次世代医療食品は、特許を取得した医薬品グレードのフィジオミミック技術を用いて開発されたもので、フェニルケトン尿症（PKU）の食事管理用に設計されています。PKUゴリケは、顆粒、分包、医療用バータイプの徐放性アミノ酸製品です。独自のコーティングにより、不快な味、におい、後味をマスキングしながら、天然タンパク質と同様のアミノ酸の生理的吸収を可能にしました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界フェニルケトン尿症（PKU） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のフェニルケトン尿症（PKU）市場：成長率分析
• 世界のフェニルケトン尿症（PKU）市場の実績：規模と成長, 2019-2024
• 世界のフェニルケトン尿症（PKU）市場の予測：規模と成長, 2024-2029, 2034F
• 世界フェニルケトン尿症（PKU）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のフェニルケトン尿症（PKU）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高フェニルアラニン血症
• マイルドなフェニルケトン尿症（PKU）
• 中等度および変異型
• クラシックフェニルケトン尿症（PKU）
• 世界のフェニルケトン尿症（PKU）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法
• 遺伝子治療
• 薬
• 食事療法
• 世界のフェニルケトン尿症（PKU）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子検査
• 生化学検査
• 新生児スクリーニング
• 世界のフェニルケトン尿症（PKU）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 専門クリニック
• 調査機関
• 在宅ヘルスケア
• 病院
• 世界のフェニルケトン尿症（PKU）市場高フェニルアラニン血症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度の高フェニルアラニン血症
• 中等度の高フェニルアラニン血症
• 重度の高フェニルアラニン血症
• 世界のフェニルケトン尿症（PKU）市場軽度フェニルケトン尿症（PKU）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食事管理による軽度のPKU
• 酵素補充による軽度のPKU
• 世界のフェニルケトン尿症（PKU）市場中等度および変異型のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物療法による中等度のPKU
• 治療が異なる変異型PKU
• 世界のフェニルケトン尿症（PKU）市場、古典的フェニルケトン尿症（PKU）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 厳格な食事管理を伴う典型的なPKU
• 酵素補充療法による古典的PKU

第7章 地域別・国別分析

• 世界のフェニルケトン尿症（PKU）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のフェニルケトン尿症（PKU）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• フェニルケトン尿症（PKU）市場：競合情勢
• フェニルケトン尿症（PKU）市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Agios Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ultragenyx Pharmaceutical Inc.
• Nutricia International Private Limited
• Codexis Inc.
• Eton Pharmaceuticals Inc.
• Vitaflo International Ltd.
• American Gene Technologies International Inc.
• Cambrooke Therapeutics Inc.
• Generation Bio Co.
• Mead Johnson & Company, LLC
• Relief Therapeutics Holding SA
• SOM Innovation Biotech S.A.
• Synlogic Inc.
• Galen Ltd
• Aptatek Biosciences Inc.
• Homology Medicines Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• フェニルケトン尿症（PKU）市場2029：新たな機会を提供する国
• フェニルケトン尿症（PKU）市場2029：新たな機会を提供するセグメント
• フェニルケトン尿症（PKU）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Phenylketonuria (PKU) is a rare inherited metabolic disorder in which the body is unable to break down the amino acid phenylalanine (Phe), which is present in many protein-containing foods. This condition results from a deficiency or malfunction of the phenylalanine hydroxylase (PAH) enzyme, which is responsible for converting phenylalanine into tyrosine.

The primary types of phenylketonuria (PKU) include hyperphenylalaninemia (HPA), mild PKU, moderate and variant PKU, and classic PKU. Hyperphenylalaninemia (HPA) is a genetic metabolic disorder caused by a deficiency of phenylalanine hydroxylase, leading to elevated levels of phenylalanine in the blood. Treatment options for PKU consist of enzyme replacement therapy, gene therapy, medication, and dietary therapy. Diagnosis methods include genetic testing, biochemical testing, and newborn screening. The key end users of PKU treatments and diagnostics include specialty clinics, research institutes, home healthcare providers, and hospitals.

The phenylketonuria (PKU) market research report is one of a series of new reports from The Business Research Company that provides phenylketonuria (PKU) market statistics, including the phenylketonuria (PKU) industry global market size, regional shares, competitors with the phenylketonuria (PKU) market share, detailed phenylketonuria (PKU) market segments, market trends, and opportunities, and any further data you may need to thrive in the phenylketonuria (PKU) industry. This phenylketonuria (PKU) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The phenylketonuria (PKU) market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to the expansion of newborn screening programs, increasing awareness of metabolic disorders, advancements in PKU dietary management, the growing availability of medical foods, and regulatory approvals for PKU treatments.

The phenylketonuria (PKU) market size is expected to see strong growth in the next few years. It will grow to $1.30 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to the increasing adoption of gene therapy, the expansion of enzyme replacement therapies, rising investments in rare disease research, growing demand for personalized medicine, and government support for PKU treatment coverage. Major trends include the development of RNA-based therapies, the rise of digital health solutions for PKU management, increased collaborations between biotech firms and research institutions, a focus on non-dietary treatment alternatives, and the expansion of telehealth services for PKU patients.

The rising incidence of genetic disorders is expected to drive the growth of the phenylketonuria (PKU) market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, including mutations, deletions, or duplications of genes or chromosomes. The increasing prevalence of these disorders can be attributed to factors such as rising maternal age, environmental influences, advancements in diagnostic technologies, and greater awareness, leading to improved detection rates. Phenylketonuria plays a key role in understanding genetic disorders by illustrating how inherited enzyme deficiencies can result in severe metabolic complications. For example, in March 2024, Gene People, a UK-based registered charity, reported that genetic conditions affect approximately 1 in 25 children, impacting over 2.4 million children and adults in the UK. Additionally, around 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. As a result, the increasing incidence of genetic disorders is fueling the expansion of the phenylketonuria (PKU) market.

Leading companies in the phenylketonuria (PKU) market are focusing on technological advancements to enhance the efficacy and safety of PKU treatments. One such innovation is the use of physiomimic technology, which replicates human physiological conditions to improve drug absorption and metabolism. Physiomimic technology comprises a set of hardware, consumables, and assay protocols designed to simulate complex human biology and precisely predict human drug responses. For instance, in October 2022, Relief Therapeutics Holding SA, a Switzerland-based biopharmaceutical company, announced the launch of PKU Golike. This next-generation medical food product, developed using patented pharmaceutical-grade physiomimic technology, is designed for the dietary management of phenylketonuria (PKU). PKU Golike is a prolonged-release amino acid product available in granules, packets, and medical food bars. Its unique coating enables the physiological absorption of amino acids similar to natural proteins while masking their unpleasant taste, odor, and aftertaste.

In August 2024, Otsuka Holdings Co. Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for approximately $1.1 billion. Through this acquisition, Otsuka Pharmaceutical gains access to JNT-517, an oral drug for treating the rare genetic disorder phenylketonuria (PKU), while also strengthening its pipeline of innovative therapies for autoimmune diseases. Jnana Therapeutics Inc. is a US-based biotechnology company specializing in the treatment of phenylketonuria (PKU).

Major players in the phenylketonuria (pku) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company, LLC, Relief Therapeutics Holding SA, SOM Innovation Biotech S.A., Synlogic Inc., Galen Ltd, Aptatek Biosciences Inc., Homology Medicines Inc.

North America was the largest region in the phenylketonuria (PKU) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in phenylketonuria (PKU) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phenylketonuria (PKU) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phenylketonuria (PKU) market consists of revenues earned by entities by provide services such as enzyme therapy, screening tests, PKU tests, and PKU formula. The market value includes the value of related goods sold by the service provider or included within the service offering. The phenylketonuria (PKU) market also includes sales of sapropterin (Kuvan), pegvaliase-pqpz (Palynziq) and dietary supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phenylketonuria (PKU) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on phenylketonuria (pku) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for phenylketonuria (pku) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phenylketonuria (pku) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hyperphenylalaninemia; Mild Phenylketonuria (PKU); Moderate And Variant; Classic Phenylketonuria (PKU)
• 2) By Treatment Type: Enzyme Replacement Therapy; Gene Therapy; Medication; Dietary Therapy
• 3) By Diagnosis: Genetic Testing; Biochemical Testing; Newborn Screening
• 4) By End-User: Specialty Clinics; Research Institutes; Home Healthcare; Hospitals
• Subsegments:
• 1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia; Moderate Hyperphenylalaninemia; Severe Hyperphenylalaninemia
• 2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management; Mild PKU with enzyme supplementation
• 3) By Moderate And Variant: Moderate PKU with medication; Variant PKU with treatment variations
• 4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management; Classic PKU with enzyme replacement therapy
• Companies Mentioned:Abbott Laboratories; Merck KGaA; Agios Pharmaceuticals Inc.; BioMarin Pharmaceutical Inc.; PTC Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Phenylketonuria (PKU) Market Characteristics

3. Phenylketonuria (PKU) Market Trends And Strategies

4. Phenylketonuria (PKU) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Phenylketonuria (PKU) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Phenylketonuria (PKU) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Phenylketonuria (PKU) Market Growth Rate Analysis
• 5.4. Global Phenylketonuria (PKU) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Phenylketonuria (PKU) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Phenylketonuria (PKU) Total Addressable Market (TAM)

6. Phenylketonuria (PKU) Market Segmentation

• 6.1. Global Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyperphenylalaninemia
• Mild Phenylketonuria (PKU)
• Moderate And Variant
• Classic Phenylketonuria (PKU)
• 6.2. Global Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Gene Therapy
• Medication
• Dietary Therapy
• 6.3. Global Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing
• Biochemical Testing
• Newborn Screening
• 6.4. Global Phenylketonuria (PKU) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specialty Clinics
• Research Institutes
• Home Healthcare
• Hospitals
• 6.5. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Hyperphenylalaninemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Hyperphenylalaninemia
• Moderate Hyperphenylalaninemia
• Severe Hyperphenylalaninemia
• 6.6. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Mild Phenylketonuria (PKU), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild PKU with dietary management
• Mild PKU with enzyme supplementation
• 6.7. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Moderate And Variant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Moderate PKU with medication
• Variant PKU with treatment variations
• 6.8. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Classic Phenylketonuria (PKU), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic PKU with strict dietary management
• Classic PKU with enzyme replacement therapy

7. Phenylketonuria (PKU) Market Regional And Country Analysis

• 7.1. Global Phenylketonuria (PKU) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Phenylketonuria (PKU) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Phenylketonuria (PKU) Market

• 8.1. Asia-Pacific Phenylketonuria (PKU) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Phenylketonuria (PKU) Market

• 9.1. China Phenylketonuria (PKU) Market Overview
• 9.2. China Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Phenylketonuria (PKU) Market

• 10.1. India Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Phenylketonuria (PKU) Market

• 11.1. Japan Phenylketonuria (PKU) Market Overview
• 11.2. Japan Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Phenylketonuria (PKU) Market

• 12.1. Australia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Phenylketonuria (PKU) Market

• 13.1. Indonesia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Phenylketonuria (PKU) Market

• 14.1. South Korea Phenylketonuria (PKU) Market Overview
• 14.2. South Korea Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Phenylketonuria (PKU) Market

• 15.1. Western Europe Phenylketonuria (PKU) Market Overview
• 15.2. Western Europe Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Phenylketonuria (PKU) Market

• 16.1. UK Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Phenylketonuria (PKU) Market

• 17.1. Germany Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Phenylketonuria (PKU) Market

• 18.1. France Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Phenylketonuria (PKU) Market

• 19.1. Italy Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Phenylketonuria (PKU) Market

• 20.1. Spain Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Phenylketonuria (PKU) Market

• 21.1. Eastern Europe Phenylketonuria (PKU) Market Overview
• 21.2. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Phenylketonuria (PKU) Market

• 22.1. Russia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Phenylketonuria (PKU) Market

• 23.1. North America Phenylketonuria (PKU) Market Overview
• 23.2. North America Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Phenylketonuria (PKU) Market

• 24.1. USA Phenylketonuria (PKU) Market Overview
• 24.2. USA Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Phenylketonuria (PKU) Market

• 25.1. Canada Phenylketonuria (PKU) Market Overview
• 25.2. Canada Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Phenylketonuria (PKU) Market

• 26.1. South America Phenylketonuria (PKU) Market Overview
• 26.2. South America Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Phenylketonuria (PKU) Market

• 27.1. Brazil Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Phenylketonuria (PKU) Market

• 28.1. Middle East Phenylketonuria (PKU) Market Overview
• 28.2. Middle East Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Phenylketonuria (PKU) Market

• 29.1. Africa Phenylketonuria (PKU) Market Overview
• 29.2. Africa Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Phenylketonuria (PKU) Market Competitive Landscape And Company Profiles

• 30.1. Phenylketonuria (PKU) Market Competitive Landscape
• 30.2. Phenylketonuria (PKU) Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Agios Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Phenylketonuria (PKU) Market Other Major And Innovative Companies

• 31.1. Ultragenyx Pharmaceutical Inc.
• 31.2. Nutricia International Private Limited
• 31.3. Codexis Inc.
• 31.4. Eton Pharmaceuticals Inc.
• 31.5. Vitaflo International Ltd.
• 31.6. American Gene Technologies International Inc.
• 31.7. Cambrooke Therapeutics Inc.
• 31.8. Generation Bio Co.
• 31.9. Mead Johnson & Company, LLC
• 31.10. Relief Therapeutics Holding SA
• 31.11. SOM Innovation Biotech S.A.
• 31.12. Synlogic Inc.
• 31.13. Galen Ltd
• 31.14. Aptatek Biosciences Inc.
• 31.15. Homology Medicines Inc.

32. Global Phenylketonuria (PKU) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Phenylketonuria (PKU) Market

34. Recent Developments In The Phenylketonuria (PKU) Market

35. Phenylketonuria (PKU) Market High Potential Countries, Segments and Strategies

• 35.1 Phenylketonuria (PKU) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Phenylketonuria (PKU) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Phenylketonuria (PKU) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer